These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36271573)

  • 1. Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy.
    Ahmed S; Alam W; Aschner M; Alsharif KF; Albrakati A; Saso L; Khan H
    Biomed Pharmacother; 2022 Nov; 155():113797. PubMed ID: 36271573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
    Edwards TG; Bloom DC; Fisher C
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
    Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
    Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
    Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconstitution of human claspin-mediated phosphorylation of Chk1 by the ATR (ataxia telangiectasia-mutated and rad3-related) checkpoint kinase.
    Lindsey-Boltz LA; Serçin O; Choi JH; Sancar A
    J Biol Chem; 2009 Nov; 284(48):33107-14. PubMed ID: 19828454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Smith J; Tho LM; Xu N; Gillespie DA
    Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    Gralewska P; Gajek A; Marczak A; Rogalska A
    J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
    Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
    Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New horizons in lung cancer management through ATR/CHK1 pathway modulation.
    Thapa R; Afzal O; Bhat AA; Goyal A; Alfawaz Altamimi AS; Almalki WH; Alzarea SI; Kazmi I; Singh SK; Dua K; Thangavelu L; Gupta G
    Future Med Chem; 2023 Oct; 15(19):1807-1818. PubMed ID: 37877252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
    Boudny M; Trbusek M
    Cancer Treat Rev; 2020 Aug; 88():102026. PubMed ID: 32592909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
    Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
    J Virol; 2019 May; 93(9):. PubMed ID: 30787154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.
    Kawasumi M; Bradner JE; Tolliday N; Thibodeau R; Sloan H; Brummond KM; Nghiem P
    Cancer Res; 2014 Dec; 74(24):7534-45. PubMed ID: 25336189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dormant origin signaling during unperturbed replication.
    Moiseeva TN; Bakkenist CJ
    DNA Repair (Amst); 2019 Sep; 81():102655. PubMed ID: 31311769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tethering DNA damage checkpoint mediator proteins topoisomerase IIbeta-binding protein 1 (TopBP1) and Claspin to DNA activates ataxia-telangiectasia mutated and RAD3-related (ATR) phosphorylation of checkpoint kinase 1 (Chk1).
    Lindsey-Boltz LA; Sancar A
    J Biol Chem; 2011 Jun; 286(22):19229-36. PubMed ID: 21502314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation.
    Luo J; Luckenbaugh L; Hu H; Yan Z; Gao L; Hu J
    mBio; 2020 Feb; 11(1):. PubMed ID: 32071277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APE2 is required for ATR-Chk1 checkpoint activation in response to oxidative stress.
    Willis J; Patel Y; Lentz BL; Yan S
    Proc Natl Acad Sci U S A; 2013 Jun; 110(26):10592-7. PubMed ID: 23754435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells.
    Jia R; Kutzner L; Koren A; Runggatscher K; Májek P; Müller AC; Schuster M; Bock C; Loizou JI; Kubicek S; Kralovics R
    Blood Cancer J; 2021 Jul; 11(7):137. PubMed ID: 34333533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.